The $1.125 million grant will go to support the development of new drug therapies for protecting the retina and optic nerve in chronic degenerative eye disease.
Research will be led by Peter Koulen, PhD, professor and endowed chair in vision research at the School of Medicine and director of basic research at the Vision Research Center.
“Degeneration or damage of the retina and the optic nerve — the nerve that connects the eye to the brain and makes vision possible — is a leading cause of loss of quality of life and productivity in the United States and worldwide,” said Dr. Koulen, in the releas. “The therapy approach we’re developing focuses on much-needed protection of nerve cells in the eye. The goal is to develop drug therapies that will be both preventative and therapeutic and complement existing treatment designs and rationales.”
Related Articles on Ophthalmology:
How ASCs Can Profit From Ophthalmology
Ophthalmologist Dr. William Constad to Receive ‘Man of Vision’ Honor
Ophthalmologist on the Move: Dr. George Baerveldt Joins CA’s NVISION Laser Eye Centers
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
